Jade Biosciences, Inc. Shareholders' Equity
Jade Biosciences, Inc. (JBIO) had Shareholders' Equity of $439.92 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-10
- 2026-06-30: Stockholders' Equity Attributable to Parent $439.92M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $296.46M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $332.52M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $179.35M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $439.92M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $296.46M 10-Q · filed 2026-08-10 | |
| 2025-12-31 | $332.52M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $179.35M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $201.56M 10-Q · filed 2026-08-10 | |
| 2025-03-31 | -$83.51M 10-Q · filed 2026-08-10 | $75.05M 10-Q · filed 2025-04-25 |
| 2024-12-31 | -$46.80M 10-Q · filed 2026-08-10 | $76.43M 10-K · filed 2025-03-27 |
| 2024-09-30 | -$16.86M 10-Q · filed 2025-11-14 | $80.49M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$589.00K 10-Q · filed 2025-11-14 | $94.40M 10-Q · filed 2024-08-12 |
| 2024-06-17 | $1.00K 10-K · filed 2026-03-06 | -$1.00K 10-Q · filed 2025-08-13 |
| 2024-03-31 | $90.90M 10-Q · filed 2025-04-25 | |
| 2023-12-31 | $109.46M 10-Q · filed 2025-04-25 | |
| 2023-09-30 | $125.72M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $141.93M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $113.09M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $126.74M 10-K · filed 2025-03-27 | |
| 2022-09-30 | $139.14M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $151.05M 10-Q · filed 2023-11-13 | |
| 2022-03-31 | $161.95M 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $172.42M 10-K · filed 2024-03-25 | |
| 2021-09-30 | $179.85M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$21.58M 10-Q · filed 2022-11-14 | |
| 2021-03-31 | -$16.11M 10-Q · filed 2022-11-14 | |
| 2020-12-31 | -$13.34M 10-K · filed 2023-03-29 | |
| 2020-09-30 | -$9.70M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$7.27M 10-Q · filed 2021-11-15 | |
| 2020-03-31 | -$5.07M 10-Q · filed 2021-11-15 | |
| 2019-12-31 | -$3.64M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |